Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments

Figures & data

Figure 1 Survival rates for patients with and without sepsis-induced DIC.

Notes: DIC was defined according to the Japanese Association for Acute Medicine DIC scores,⁴⁹ as a score of ࣙ4 on ICU admission. Reproduced from Hayakawa M, Saito S, Uchino S, et al. Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011ߝ2013. J Intensive Care. 2016;4:44.⁴
Abbreviations: DIC, disseminated intravascular coagulation; ICU, intensive care unit.

Table 1 Drugs and frequency of DIC treatments

Japan-Septic DIC study, 3,195 patients with sepsis treated in ICU^Citation4
Any DIC treatments	47%
Antithrombin	31%
Thrombomodulin	27%
Co-administration of antithrombin and thrombomodulin	16%
Protease inhibitors	12%
Heparinoids	5%
Japanese national administrative database, 14,324 patients with sepsis-induced DiC^Citation11
Antithrombin	42%
Thrombomodulin	44%
Protease inhibitors	11%
Heparin	30%
International sepsis registry, 12,881 patients with sepsis treated in ICU^Citation12
Antithrombin	3%

Abbreviations: DIC, disseminated intravascular coagulation; ICU, intensive care unit.

Figure 2 Survival rates for patients in the propensity score-matched control and rhTM groups.

Note: Reproduced from Hayakawa M, Yamakawa K, Saito S, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115(6):1157ߝ1166.³⁸
Abbreviations: rhTM, recombinant human soluble thrombomodulin; ICU, intensive care unit.

Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625–631.

 PubMed Web of Science ®Google Scholar

Hayakawa M, Saito S, Uchino S, et al. Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011-2013. J Intensive Care. 2016;4:44.

 PubMed Web of Science ®Google Scholar

Murata A, Okamoto K, Mayumi T, Muramatsu K, Matsuda S. Recent change in treatment of disseminated intravascular coagulation in Japan: an epidemiological study based on a national administrative database. Clin Appl Thromb Hemost. 2016;22(1):21–27.

 PubMed Web of Science ®Google Scholar

Beale R, Reinhart K, Brunkhorst FM, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection. 2009;37(3):222–232.

 PubMed Web of Science ®Google Scholar

Hayakawa M, Yamakawa K, Saito S, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115(6):1157–1166.

 PubMed Web of Science ®Google Scholar